

Gregory S Calip

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6101499/publications.pdf>

Version: 2024-02-01

147
papers

1,831
citations

377584

21
h-index

388640

36
g-index

149
all docs

149
docs citations

149
times ranked

3114
citing authors

#	ARTICLE	IF	CITATIONS
1	Serious opioid-related adverse outcomes associated with opioids prescribed by dentists. <i>Pain</i> , 2022, 163, 1571-1580.	2.0	7
2	The association between physical health-related quality of life, physical functioning, and risk of contralateral breast cancer among older women. <i>Breast Cancer</i> , 2022, 29, 287-295.	1.3	4
3	Appropriateness of Antibiotic Prophylaxis Before Dental Procedures, 2016–2018. <i>American Journal of Preventive Medicine</i> , 2022, 62, 943-948.	1.6	11
4	Trends in Opioid Prescribing by General Dentists and Dental Specialists in the U.S., 2012–2019. <i>American Journal of Preventive Medicine</i> , 2022, 63, 3-12.	1.6	8
5	Impact of time to distant recurrence on breast cancer-specific mortality in hormone receptor-positive breast cancer. <i>Cancer Causes and Control</i> , 2022, , 1.	0.8	0
6	Disparities in cardiovascular disease mortality after breast cancer treatment: Methodological considerations using real-world data. <i>Cancer</i> , 2022, 128, 647-650.	2.0	2
7	Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States. <i>Journal of the National Cancer Institute</i> , 2022, 114, 571-578.	3.0	8
8	Physical functioning, frailty and risks of locally-advanced breast cancer among older women. <i>Breast</i> , 2022, 64, 19-28.	0.9	0
9	Impact of socioeconomic status and rurality on cancer-specific survival among women with de novo metastatic breast cancer by race/ethnicity. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 707-716.	1.1	11
10	Health-related Quality of Life in Hormone Receptor-Positive Early Breast Cancer: Analyses From the Surveillance, Epidemiology, and End Results Medicare Health Outcomes Survey. <i>Journal of Patient Experience</i> , 2022, 9, 237437352211130.	0.4	0
11	Barriers to and facilitators of opioid prescribing by dentists in the United States. <i>Journal of the American Dental Association</i> , 2022, , .	0.7	0
12	Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 579-587.	0.5	1
13	Exploring Completeness of Adverse Event Reports as a Tool for Signal Detection in Pharmacovigilance. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 142-151.	0.8	4
14	Serious antibiotic-related adverse effects following unnecessary dental prophylaxis in the United States. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 110-112.	1.0	18
15	Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 195-204.	1.1	10
16	Factors influencing antibiotic duration in culture-negative neonatal early-onset sepsis. <i>Pharmacotherapy</i> , 2021, 41, 148-161.	1.2	6
17	Racial Disparities in Intravenous Bisphosphonate Use Among Older Patients With Multiple Myeloma Enrolled in Medicare. <i>JCO Oncology Practice</i> , 2021, 17, e294-e312.	1.4	7
18	Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women. <i>JAMA Oncology</i> , 2021, 7, 370.	3.4	64

#	ARTICLE	IF	CITATIONS
19	Trend in Tyrosine Kinase Inhibitor Utilization, Price, and Out-of-Pocket Costs in Patients With Chronic Myelogenous Leukemia. <i>JCO Oncology Practice</i> , 2021, 17, e1811-e1820.	1.4	8
20	Characteristics Associated With Opioid and Antibiotic Prescribing by Dentists. <i>American Journal of Preventive Medicine</i> , 2021, 60, 648-657.	1.6	17
21	Early-onset pancreatic cancer research: Making sense of confounding and bias. <i>Cancer</i> , 2021, 127, 3505-3507.	2.0	4
22	Associations between frailty and cancer-specific mortality among older women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 769-779.	1.1	10
23	Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma. <i>JAMA Network Open</i> , 2021, 4, e2118410.	2.8	1
24	Risk of fall-related injury and all-cause hospitalization of select concomitant central nervous system medication prescribing in older adult persistent opioid users: A case-time-control analysis. <i>Pharmacotherapy</i> , 2021, 41, 733-742.	1.2	1
25	Population-based recurrence rates among older women with HR-positive, HER2-negative early breast cancer: Clinical risk factors, frailty status, and differences by race. <i>Breast</i> , 2021, 59, 367-375.	0.9	3
26	Type 2 diabetes mellitus burdens among adults with sickle cell disease: A 12-year single health system-based cohort analysis. <i>EJHaem</i> , 2021, 2, 97-101.	0.4	0
27	Chronic Opioid Use Is Highly Prevalent in Patients Undergoing Allogeneic Transplant and Impacts Long Term Outcomes. <i>Blood</i> , 2021, 138, 1823-1823.	0.6	2
28	Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database. <i>Blood</i> , 2021, 138, 4121-4121.	0.6	0
29	Racial Disparities in the Diagnostic Evaluation of Multiple Myeloma. <i>Blood</i> , 2021, 138, 4116-4116.	0.6	3
30	Social and Demographic Factors Contributing to COVID-19 Vaccine Hesitancy in Patients with Hematologic Malignancies. <i>Blood</i> , 2021, 138, 841-841.	0.6	1
31	Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 199-206.	1.3	12
32	Metastatic breast cancer survival improvement restricted by regional disparity: Surveillance, Epidemiology, and End Results and institutional analysis: 1990 to 2011. <i>Cancer</i> , 2020, 126, 390-399.	2.0	23
33	Clinical trajectories, healthcare resource use, and costs of long-term hematopoietic stem cell transplantation survivors: a latent class analysis. <i>Journal of Cancer Survivorship</i> , 2020, 14, 294-304.	1.5	9
34	Association of Insurance Status and Racial Disparities With the Detection of Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 385.	3.4	128
35	Prevalence of Cardiac Risk Factors in Patients Prescribed Azithromycin before and after the 2012 FDA Warning on the Risk of Potentially Fatal Heart Rhythms. <i>Pharmacotherapy</i> , 2020, 40, 107-115.	1.2	10
36	Depressive symptoms, mental health-related quality of life, and survival among older patients with multiple myeloma. <i>Supportive Care in Cancer</i> , 2020, 28, 4097-4106.	1.0	12

#	ARTICLE	IF	CITATIONS
37	Impact of adverse event reports from marketing authorization holder-sponsored patient support programs on the performance of signal detection in pharmacovigilance. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1357-1366.	1.0	4
38	Immigration Status and Disparities in the Treatment of Cardiovascular Disease Risk Factors in the Hispanic Community Health Study/Study of Latinos (Visit 2, 2014-2017). <i>American Journal of Public Health</i> , 2020, 110, 1397-1404.	1.5	16
39	Potentially Inappropriate Medication Combination with Opioids among Older Dental Patients: A Retrospective Review of Insurance Claims Data. <i>Pharmacotherapy</i> , 2020, 40, 992-1001.	1.2	5
40	Risks of Second Primary Gynecologic Cancers following Ovarian Cancer Treatment in Asian Ethnic Subgroups in the United States, 2000-2016. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2220-2229.	1.1	0
41	Risk of cardiac events with azithromycin—A prediction model. <i>PLoS ONE</i> , 2020, 15, e0240379.	1.1	0
42	Comparison of Cardiac Events Associated With Azithromycin vs Amoxicillin. <i>JAMA Network Open</i> , 2020, 3, e2016864.	2.8	6
43	Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2165-2173.	1.1	5
44	PARP Inhibition Synergizes with Melphalan but Does not Reverse Resistance Completely. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1273-1279.	2.0	8
45	Citizenship Status and the Prevalence, Treatment, and Control of Cardiovascular Disease Risk Factors Among Adults in the United States, 2011-2016. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006215.	0.9	21
46	Overprescribing of Opioids to Adults by Dentists in the U.S., 2011-2015. <i>American Journal of Preventive Medicine</i> , 2020, 58, 473-486.	1.6	43
47	Maximizing Breast Cancer Therapy with Awareness of Potential Treatment-Related Blood Disorders. <i>Oncologist</i> , 2020, 25, 391-397.	1.9	13
48	Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma. <i>International Journal of Cancer</i> , 2020, 147, 1300-1305.	2.3	6
49	Self-reported health and survival in older patients diagnosed with multiple myeloma. <i>Cancer Causes and Control</i> , 2020, 31, 641-650.	0.8	7
50	A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 937-943.	2.0	3
51	First trimester use of artemisinin-based combination therapy and the risk of low birth weight and small for gestational age. <i>Malaria Journal</i> , 2020, 19, 144.	0.8	8
52	Metastatic-free intervals and risk of breast cancer-specific mortality among patients with hormone receptor-positive breast cancer: A population-based analysis from the Surveillance, Epidemiology, and End Results registries. <i>Journal of Clinical Oncology</i> , 2020, 38, e13034-e13034.	0.8	0
53	Real-world patterns of treatment and recurrence by frailty status among older women with HR-positive, HER2-negative early breast cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 535-535.	0.8	0
54	HSR20-113: Diabetes Complications and Risks of Breast Cancer Recurrence Among Older Women. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, HSR20-113.	2.3	1

#	ARTICLE	IF	CITATIONS
55	Increased DNA Repair Gene Expression Correlates with MYC Expression and Inferior Progression-Free Survival in Multiple Myeloma Patients. <i>Blood</i> , 2020, 136, 48-49.	0.6	1
56	High Rates of Varicella Zoster Virus Antibody Seroconversion and Persistence after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment. <i>Blood</i> , 2020, 136, 50-50.	0.6	1
57	Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant. <i>Blood</i> , 2020, 136, 19-20.	0.6	0
58	Hematologic Predictors of Outcomes in Patients Undergoing Intensive Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 39-40.	0.6	0
59	Risk of cardiac events with azithromycinâ€”A prediction model. , 2020, 15, e0240379.		0
60	Risk of cardiac events with azithromycinâ€”A prediction model. , 2020, 15, e0240379.		0
61	Risk of cardiac events with azithromycinâ€”A prediction model. , 2020, 15, e0240379.		0
62	Risk of cardiac events with azithromycinâ€”A prediction model. , 2020, 15, e0240379.		0
63	Pretransplant hemoglobin and creatinine clearance correlate with treatment-free survival after autologous stem cell transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2081-2087.	1.3	5
64	Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with Highâ€”Grade Gliomas: A Nested Caseâ€”Control Study. <i>Pharmacotherapy</i> , 2019, 39, 921-928.	1.2	8
65	Older Medicare Beneficiaries Frequently Continue Medications with Limited Benefit Following Hospice Admission. <i>Journal of General Internal Medicine</i> , 2019, 34, 2029-2037.	1.3	10
66	Superior Survival in African American Patients Who Underwent Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e506-e511.	0.2	7
67	Sodiumâ€”glucose coâ€”transporter 2 inhibitors and the risk of fractures: A propensity scoreâ€”matched cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1629-1639.	0.9	21
68	Type 2 diabetes in adults with sickle cell disease: can we dive deeper? Response to Skinner <i><i>etÂ</i>	1.2	0
69	Discontinuation and Nonadherence to Medications for Chronic Conditions after Hematopoietic Cell Transplantation: A 6â€”Year Propensity Scoreâ€”Matched Cohort Study. <i>Pharmacotherapy</i> , 2019, 39, 55-66.	1.2	8
70	Comparison of Opioid Prescribing by Dentists in the United States and England. <i>JAMA Network Open</i> , 2019, 2, e194303.	2.8	75
71	Assessment of the Appropriateness of Antibiotic Prescriptions for Infection Prophylaxis Before Dental Procedures, 2011 to 2015. <i>JAMA Network Open</i> , 2019, 2, e193909.	2.8	110
72	Granulocyte Colony-Stimulating Factors in Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2019, 5, 1065.	3.4	0

#	ARTICLE	IF	CITATIONS
73	Diabetes and differences in detection of incident invasive breast cancer. <i>Cancer Causes and Control</i> , 2019, 30, 435-441.	0.8	6
74	Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis. <i>British Journal of Haematology</i> , 2019, 185, 116-127.	1.2	14
75	The morbidity and mortality of end stage renal disease in sickle cell disease. <i>American Journal of Hematology</i> , 2019, 94, E138-E141.	2.0	11
76	How Did Research on Medication Safety in Pregnancy Define, Develop and Advance the Field of Pharmacoepidemiology?. <i>Clinical Therapeutics</i> , 2019, 41, 2464-2466.	1.1	1
77	Mediation analyses of socioeconomic factors determining racial differences in the treatment of diffuse large B-cell lymphoma in a cohort of older adults. <i>Medicine (United States)</i> , 2019, 98, e17960.	0.4	3
78	Use of Nonpalliative Medications Following Burdensome Health Care Transitions in Hospice Patients. <i>Medical Care</i> , 2019, 57, 13-20.	1.1	6
79	Renal dysfunction within 90 days of FluBu4 predicts early and late mortality. <i>Bone Marrow Transplantation</i> , 2019, 54, 980-986.	1.3	4
80	Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma. <i>Cancer</i> , 2019, 125, 1143-1154.	2.0	14
81	Increased risk of mycotic infections associated with sodium-glucose co-transporter 2 inhibitors: a prescription sequence symmetry analysis. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 160-168.	1.1	22
82	Treatment of older patients with diffuse large B-cell lymphoma and mild cognitive impairment or dementia. <i>Journal of Geriatric Oncology</i> , 2019, 10, 510-513.	0.5	4
83	High Rates of Varicella Zoster Virus Antibody Seroconversion after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment. <i>Blood</i> , 2019, 134, 3081-3081.	0.6	4
84	Depressive symptoms, mental health-related quality of life, and survival among older patients with multiple myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, e18232-e18232.	0.8	0
85	Low Pre-Treatment Hemoglobin and Creatinine Clearance Correlate with Worse Overall Survival, Treatment-Related Mortality, and Regimen-Related Toxicities in Patients Undergoing a Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine and Melphalan. <i>Blood</i> , 2019, 134, 1980-1980.	0.6	1
86	Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant. <i>Blood</i> , 2019, 134, 3310-3310.	0.6	0
87	Medicare Part D Use of Older Medicare Beneficiaries Admitted to Hospice. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 937-944.	1.3	6
88	Tumor necrosis factor- α inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. <i>International Journal of Cancer</i> , 2018, 143, 1062-1071.	2.3	42
89	Combined Immune Score of Lymphocyte to Monocyte Ratio and Immunoglobulin Levels Predicts Progression-Free Survival of Myeloma Patients after Autologous Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S78-S79.	2.0	0
90	The impact of depression medications on oral antidiabetic drug adherence in patients with diabetes and depression. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 492-500.	1.2	6

#	ARTICLE	IF	CITATIONS
91	Risk of Serious Bacterial Infection Associated With Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 883-891.	0.9	9
92	Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2018, 57, 273-282.	0.9	23
93	Erythropoiesis-stimulating agents in sickle cell anaemia. <i>British Journal of Haematology</i> , 2018, 182, 602-605.	1.2	9
94	Characterization of opioid use in sickle cell disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 479-486.	0.9	37
95	Similar Survival but Increased Toxicity with a Sequential Versus Concurrent FluBu4 Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S305-S306.	2.0	0
96	Predicting Acute Exacerbations in Chronic Obstructive Pulmonary Disease. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 265-279.	0.5	8
97	Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study. <i>British Journal of Haematology</i> , 2018, 182, 259-270.	1.2	16
98	Risk of amputations associated with SGLT2 inhibitors compared to DPP4 inhibitors: A propensity-matched cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2792-2799.	2.2	52
99	Similar survival but increased toxicity with a sequential versus concurrent FluBu4 regimen. <i>Bone Marrow Transplantation</i> , 2018, 53, 1221-1224.	1.3	0
100	A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1397-1397.	0.6	3
101	Type 2 Diabetes Mellitus in Patients with Sickle Cell Disease: A Population-Based Longitudinal Analysis of Three Cohorts. <i>Blood</i> , 2018, 132, 4817-4817.	0.6	2
102	Risk of Diabetes Hospitalization or Diabetes Drug Intensification in Patients With Depression and Diabetes Using Second-Generation Antipsychotics Compared to Other Depression Therapies. <i>primary care companion for CNS disorders, The</i> , 2018, 20, .	0.2	3
103	Abstract P6-08-11: Regional variation in de novo metastatic breast cancer survival improvement over time using an institutional registry to support SEER analysis: 1990-2010. , 2018, , .		0
104	Abstract 4225: Myelodysplastic syndrome and acute myeloid leukemia following use of chemo-immunotherapy and granulocyte colony-stimulating factors among elderly non-Hodgkin lymphoma patients. , 2018, , .		0
105	Venous Thromboembolic Prophylaxis Following Treatment Initiation for Multiple Myeloma. <i>Blood</i> , 2018, 132, 4693-4693.	0.6	0
106	Pre-Transplant Hemoglobin and Creatinine Clearance Correlate with Treatment Free Survival in Patients with Myeloma Receiving Mel200 and Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 4621-4621.	0.6	0
107	A Risk Assessment Model for the Identification of Sickle Cell Disease Patients at Risk for Venous Thromboembolism. <i>Blood</i> , 2018, 132, 3568-3568.	0.6	0
108	Biologic Disease-Modifying Antirheumatic Drugs and Risk of Multiple Myeloma. <i>Blood</i> , 2018, 132, 1888-1888.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Collaborative Physician-Pharmacist Managed Multiple Myeloma Clinic Decreases Polypharmacy, Improves Guideline Adherence, and Prevents Treatment Delays. <i>Blood</i> , 2018, 132, 3542-3542.	0.6	0
110	A New Prognostic Score Using Lymphocyte to Monocyte Ratio and Immunoglobulin Levels to Predict Progression in Multiple Myeloma Patients Undergoing Autologous Transplant. <i>Blood</i> , 2018, 132, 3442-3442.	0.6	0
111	Comparative Effectiveness of Long-Acting Beta ₂ -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease. <i>Pharmacotherapy</i> , 2017, 37, 447-455.	1.2	18
112	Acute Kidney Injury before Day 90 Predicts for Poor Overall Survival after FluBu4. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S303-S304.	2.0	0
113	Improved Survival in African American Patients Undergoing Autologous Transplant for Multiple Myeloma in the Chemotherapy and Novel Agent Era. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S144.	2.0	0
114	Medication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditions. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 157-164.	1.6	40
115	Evidence for Detection Bias by Medication Use in a Cohort Study of Breast Cancer Survivors. <i>American Journal of Epidemiology</i> , 2017, 185, 661-672.	1.6	14
116	Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting Î2-Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid. <i>Annals of Pharmacotherapy</i> , 2017, 51, 945-953.	0.9	19
117	Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemia among breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 161-172.	1.1	32
118	Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer â€” a SEER analysis. <i>BMC Cancer</i> , 2017, 17, 659.	1.1	8
119	Polypharmacy and Adherence to Adjuvant Endocrine Therapy for Breast Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e451-e462.	2.5	37
120	First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: A meta-analysis of observational studies. <i>PLoS Medicine</i> , 2017, 14, e1002290.	3.9	66
121	Weekly miscarriage rates in a community-based prospective cohort study in rural western Kenya. <i>BMJ Open</i> , 2016, 6, e011088.	0.8	32
122	Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study. <i>Cancer Causes and Control</i> , 2016, 27, 709-720.	0.8	17
123	PD09-08 SHOULD A MAN WITH A HISTORY OF BREAST CANCER BE SCREENED FOR PROSTATE CANCER?. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
124	Utilization of Tumor Necrosis Factor Alpha Inhibitors in Children and Young Adults with Juvenile Idiopathic Arthritis. <i>Value in Health</i> , 2016, 19, A227.	0.1	0
125	Therapy-related myelodysplastic syndrome following primary breast cancer. <i>Leukemia Research</i> , 2016, 47, 178-184.	0.4	14
126	Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis. <i>Pharmacotherapy</i> , 2016, 36, 1201-1209.	1.2	10

#	ARTICLE	IF	CITATIONS
127	Top-down Versus Step-up Prescribing Strategies for Tumor Necrosis Factor Alpha Inhibitors in Children and Young Adults with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2410-2417.	0.9	15
128	Risk of cancer-specific, cardiovascular, and all-cause mortality among Asian and Pacific Islander breast cancer survivors in the United States, 1991â€“2011. <i>SpringerPlus</i> , 2016, 5, 82.	1.2	16
129	Race and Socioeconomic Factors Influencing Treatment Disparities and Comparative Effectiveness in Very Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 841-841.	0.6	0
130	Racial Differences in Long-Term Risk of Venous Thromboembolism Among Older Patients Following Diagnosis and Treatment of Multiple Myeloma. <i>Blood</i> , 2016, 128, 2071-2071.	0.6	0
131	Assessment of the safety of antimalarial drug use during early pregnancy (ASAP): protocol for a multicenter prospective cohort study in Burkina Faso, Kenya and Mozambique. <i>Reproductive Health</i> , 2015, 12, 112.	1.2	20
132	Risks of miscarriage and inadvertent exposure to artemisinin derivatives in the first trimester of pregnancy: a prospective cohort study in western Kenya. <i>Malaria Journal</i> , 2015, 14, 461.	0.8	23
133	Effect of treatment and mammography detection on breast cancer survival over time: 1990â€“2007. <i>Cancer</i> , 2015, 121, 2553-2561.	2.0	55
134	Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 75-85.	0.9	42
135	Racial and ethnic differences in risk of second primary cancers among breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 687-696.	1.1	21
136	Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 133-143.	1.1	27
137	Associations between diabetes medication use and risk of second breast cancer events and mortality. <i>Cancer Causes and Control</i> , 2015, 26, 1065-1077.	0.8	31
138	Long Term Statin Use and Risk of Multiple Myeloma Among 15.5 Million Taiwanese Adults: A Retrospective Cohort Study. <i>Blood</i> , 2015, 126, 4198-4198.	0.6	4
139	Abstract PD4-6: Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemias among breast cancer survivors. , 2015, , .		0
140	Risk of Non-Hodgkin Lymphoma Following Treatment of Inflammatory Conditions with Tumor Necrosis Factor-Alpha Inhibitors. <i>Blood</i> , 2015, 126, 2653-2653.	0.6	0
141	Tumor Necrosis Factor-Alpha Inhibitor Medications for Inflammatory Conditions and Incidence of Multiple Myeloma. <i>Blood</i> , 2015, 126, 2954-2954.	0.6	1
142	Metabolic syndrome and outcomes following early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 363-377.	1.1	73
143	Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 629-636.	1.1	17
144	Impact of the Family Health Program on gastroenteritis in children in Bahia, Northeast Brazil: An analysis of primary care-sensitive conditions. <i>Journal of Epidemiology and Global Health</i> , 2013, 3, 175.	1.1	10

#	ARTICLE	IF	CITATIONS
145	Evaluation of seasonality in the diagnosis of acute myeloid leukaemia among adults in the United States, 1992–2008. <i>British Journal of Haematology</i> , 2013, 160, 343-350.	1.2	9
146	Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 225-233.	1.1	34
147	Indications For and Use of Nonsteroidal Antiinflammatory Drugs and the Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial. <i>American Journal of Epidemiology</i> , 2012, 176, 156-163.	1.6	23